Perindopril, an angiotensin converting enzyme inhibitor, in pulmonary hypertensive rats: Comparative effects on pulmonary vascular structure and function

British Journal of Pharmacology

Volumn 128, Issue 7, 1999, Pages 1407-1418

  Jeffery, Trina K ^a   Wanstall, Janet C ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

ACE inhibitor; Chronic hypoxia; Isolated lungs; Perindopril; Pulmonary artery; Pulmonary hypertension; Pulmonary vascular function; Pulmonary vascular remodelling

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLCHOLINE; ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL; SEROTONIN; THROMBOXANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HISTOLOGY; HYPOXIA; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG CLOSING VOLUME; LUNG PERFUSION; LUNG VASOCONSTRICTION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; STRUCTURE ACTIVITY RELATION;

EID: 0032704842     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702923     Document Type: Article

References (46)

1. ALPERT, M.A., PRESSLY, T.A., MUKERJI, V., LAMBERT, C.R. & MUKERJI, B. (1992). Short-and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. Chest, 102, 1407-1412.
2. ALTIERE, R.J., OLSON, J.W. & GILLESPIE, M.N. (1986). Altered pulmonary vascular smooth muscle responsiveness in monocrotaline-induced pulmonary hypertension. J. Pharmacol. Exp. Ther., 236, 390-395.
3. BEE, D. & WACH, R.A. (1984). Hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Respir. Physiol., 56, 91-103.
4. BISHOP, J.E., BUTT, R.P. & LOW, R.B. (1995). The effect of mechanical forces on cell function: implications for pulmonary vascular remodelling due to hypertension. In: Pulmonary vascular remodelling, eds. Bishop, J.E., Reeves, J.T. & Laurent, G.J. pp. 213-239. London: Portland Press.
5. CACOUB, P., DORENT, R., NATAF, P. & CARAYON, A. (1993). Endothelin-1 in pulmonary hypertension. N. Engl. J. Med., 329, 1967-1968.
6. CLOZEL, J., SAUNIER, C., HARTEMANN, D. & FISCHLI, W. (1991). Effects of cilazapril, a novel angiotensin converting enzyme inhibitor, on the structure of pulmonary arteries of rats exposed to chronic hypoxia. J. Cardiovase. Pharmacol., 17, 36-40.
7. DINII-XUAN, A.T. (1993). Disorders of endothelium-dependent relaxation in pulmonary disease. Circulation. 87, V81-V87.
8. DUSTING, G., HYLAND, R., HICKEY, H. & MAKDISSI, M. (1995). Angiotensin-converting enzyme inhibitors reduce neointimal thickening and maintain endothelial nitric oxide function in rabbit carotid arteries. Am. J. Cardiol., 76, 24E-27E.
9. EMERY, C.J., BEE, D. & BARER, G. (1981). Mechanical properties and reactivity of vessels in isolated perfused lungs of chronically hypoxic rats. Clin. Sci., 61, 569-580.
10. GAINE, S.P. & RUBIN, L.J. (1998). Primary pulmonary hypertension. Lancet. 352, 719-725.
11. GILLESPIE, M.N., LIPKE, D.W. & MCMURTRY, I.F. (1995). Regulation of pulmonary vasomotor tone in hypertensive pulmonary vascular remodelling. In: Pulmonary vascular remodelling, eds. Bishop, J.E., Reeves, J.T. & Laurent, G.J. pp. 117-147. London: Portland Press.
12. HERGET, J., PELOUCH, V., KOLAR, F. & OSTADAL, B. (1996). The inhibition of angiotensin converting enzyme attenuates the effects of chronic hypoxia on pulmonary blood vessels in the rat. Physiol. Res., 45, 221-226.
13. HOMER, K.L., GAMBINO, A. & WANSTALL, J.C. (1996). Responses to vasoconstrictors in conduit and resistance pulmonary arteries are enhanced in hypoxic pulmonary hypertension. Proc. Aust. Soc. Clin. Exp. Pharmacol. Toxicol., 3, 91.
14. ITO, K., NAKASHIMA, T., MURAKAMI, K. & MURAKAMI, T. (1988). Altered function of pulmonary endothelium following monocrotaline-induced lung vascular injury in rats. Br. J. Pharmacol., 94, 1175-1183.
15. JACKSON, B., CUBELA, R.B. & JOHNSTON, C.I. (1988). Inhibition of tissue angiotensin converting enzyme by perindopril: in vivo assessment in the rat using radioinhibitor binding displacement. J. Pharmacol Exper. Therap., 245, 950-955.
16. JEFFERY, T.K. & WANSTALL, J.C. (1998a). Perindopril (angiotensin converting enzyme inhibitor) attenuates pulmonary vascular remodelling in hypoxic pulmonary hyeprtensive rats. Proc. Aust. Soc. Clin. Exp. Pharmacol. Toxicol., 5, 24.
17. JEFFERY, T.K. & WANSTALL, J.C. (1998b). Phosphodiesterase III and V inhibitors on pulmonary artery from pulmonary hypertensive rats: differences between early and established pulmonary hypertension. J. Cardiovase. Pharmacol., 32, 213-219.
18. JEFFERY, T.K. & WANSTALL, J.C. (1999). An angiotensin converting enzyme (ACE) inhibitor, perindopril, in pulmonary hypertensive rats: contrasting effects on pulmonary vascular function and structure. Fund. Clin. Pharmacol., 13, 156s.
19. JOHNSTON, C.I. (1990). Biochemistry and pharmacology of the renin-angiotensin system. Drugs, 39, 21-31.
20. LEIER, C.V., BAMBACH, D., NELSON, S., JERMILLER, J.B., HUSS, P., MAGORIEN, R.D. & UNVERFERTH, D.V. (1983). Captopril in primary pulmonary hypertension. Circulation, 67, 155-161.
21. LEVY, B.I., MICHEL, J.B., SALZMANN, J.L., DEVISSAGUET, M., CAMILLERI, J.P. & SAFAR, M.E. (1989). Effects of chronic converting enzyme inhibition on the structure and function of large arteries in the rat. Clin. Exper. Theory and Practice, A11, 487-498.
22. MACLEAN, M.R., SWEENEY, G., BAIRD, M., MCCULLOCH, K.M., HOUSLAY, M. & MORECROFT, I. (1996). 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br. J. Pharmacol., 119, 917-930.
23. MADDEN, J.A., KELLER, P.A., EFFROS, R.M., SEAVITTE, C., CHOY, J.S. & HACKER, A.D. (1994). Responses to pressure and vasoactive agents by isolated pulmonary arteries from monocrotaline-treated rats. J. Appl. Physiol., 76, 1589-1593.
24. MARTIN, I., BASSO, N., SARCHI, M.I. & TAQUINI, A.C. (1987). Changes in the renin-angiotensin-aldosterone system in rats of both sexes submitted to chronic hypobaric hypoxia. Arch. Int. Physiol. Biochim., 95, 255-262.
25. MINAMI, N. & HEAD, G.A. (1993). Relationship between cardiovascular hypertrophy und cardiac baroreflex function in spontaneously hypertensive and stroke-prone rats. J. Hypertension, 11, 523-533.
26. MORRELL, N.W., ATOCHINA, E.N., MORRIS, K.G., DANILOV, S.M. & STENMARK, K.R. (1995a). Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. J. Clin. Invest., 96, 1823-1833.
27. MORRELL, N.W., DANILOV, S.M., SATYAN, K.B., MORRIS, K.G. & STENMARK, K.R. (1997). Right ventricular angiotensin converting enzyme activity and expression is increased during hypoxic pulmonary hypertension. Cardiovase. Res., 34, 393-403.
28. MORRELL, N.W., MORRIS, K.G. & STENMARK, K.R. (1995b). Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am. J. Physiol., 269, H1186-H1194.
29. MURPHY, R.A. (1980). Mechanics of vascular smooth muscle. In: Handbook of physiology, the cardiovascular system, eds. Bohr, P.F., Somylo, A.P. & Sparks, H.V. Sect. 2, Vol. 2, pp. 325-351. Bethesda, MD: American Physiological Society.
30. NIAZOVA, Z.A., BATYRALIEV, T.A., AIKIMBAEV, K.S., KUDAIBERDIEVA, G.Z., AKGUL, F., SOODANBEKOVA, Y.K. & BIRAND, A. (1996). High-altitude pulmonary hypertension: effects of captopril on pulmonary and systemic arterial pressure. J. Hum. Hypertens., 10, S141-142.
31. NONG, Z., STASSEN, J., MOONS, L., COLLEN, D. & JANSSENS, S. (1996). Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodelling. Circulation, 94, 1941-1947.
32. ODDOY, A., BEE, D., EMERY, C. & BARER, G. (1991). Effects of ligustrazine on the pressure/flow relationship in isolated perfused rat lungs, Eur. Respir. J., 4, 1223-1227.
33. OKADA, K., BERNSTEN, M.L., ZHANG, W., SCHUSTER, D.P. & BOTNEY, M.D. (1998). Angiotensin-converting enzyme inhibition delays pulmonary vascular neointimal formation. Am. J. Respir. Crit. Care Med., 158, 939-950.
34. PISON, C.M., WOLF, J.E., LEVY, P.A., DUBOIS, F., BRAMBILLA, C.G. & PARAMELLE, B. (1991). Effects of captopril combined with oxygen therapy at rest and on exercise in patients with chronic bronchitis and pulmonary hypertension. Respiration, 58, 9-14.
35. PREWITT, R.L. & LEFFLER, C.W. (1981). Feline hypoxic pulmonary vasoconstriction is not blocked by the angiotensin I-converting enzyme inhibitor, captopril. J. Cardiovase. Pharmacol., 3, 293-298.
36. REID, L.M. (1979). The pulmonary circulation; remodelling in growth and disease. Am. Rev. Respir. Dis., 119, 531-546.
37. RUSSELL, P.C., EMERY, C., CAI, Y.N., BARER, G. & HOWARD, P. (1990). Enhanced reactivity to bradykinin, angiotensin I and the effect of captopril in the pulmonary vasculature of chronically hypoxic rats. Eur. Respir. J., 3, 779-785.
38. SAKAGUCHI, K., JACKSON, B., CHAI, S.C., MENDELSOHN, F.A.O. & JOHNSTON, C.I. (1988). Effects of perindopril on tissue angiotensin-converting enzyme activity demonstrated by quantitative in vitro radiography. J. Cardiovase. Pharmacol., 12, 710-717.
39. SALVETTI, A. (1990). Newer ACE inhibitors. Drugs, 40, 800-828.
40. THOMAS, W.G. & SERNIA, C. (1988). Immunocytochemical localization of angiotensinogen in the rat brain. Neuroscience, 25, 319-341.
41. VANHOUTTE, P.M., AUCH-SCHWELK, M.L., BIONDI, M.L., LORENZ, R.R. & SCHINI, V.B. (1989). Why are converting enzyme inhibitors vasodilators? Br. J. Clin. Pharmacol., 28, 95S-104S.
42. VRANES, D., COOPER, M. & DILLEY, R. (1995). Angiotensin-converting enzyme inhibition reduces diabetes-induced vascular hypertrophy: morphometric studies. J. Vasc. Res., 32, 183-189.
43. WANSTALL, J.C., HUGHES, I.E. & O'DONNELL, S.R. (1992). Reduced relaxant potency of nitroprusside on pulmonary artery preparations taken from rats during the development of hypoxic pulmonary hypertension. Br. J. Pharmacol., 107, 407-413.
44. WANSTALL, J.C., HUGHES, I.E. & O'DONNELL, S.R. (1995). Evidence that nitric oxide from the endothelium attenuates inherent tone in isolated pulmonary arteries from rats with hypoxic pulmonary hypertension. Br. J. Pharmacol., 114, 109-114.
45. WANSTALL, J.C. & JEFFERY, T.K. (1998). Recognition and management of pulmonary hypertension. Drugs, 56, 989-1007.
46. WANSTALL, J.C. & O'DONNELL, S.R. (1992). Responses to vasodilator drugs on pulmonary artery preparations from pulmonary hypertensive rats. Br. J. Pharmacol., 105, 152-158.